Drug discovery is entering a period of profound transformation, driven by an explosion in data generation, advanced automation, and the game-changing power of artificial intelligence. To explore this new frontier, we’re launching Models & Molecules, a new interview series about the innovation at the intersection of biology and computational science. Join host Nicola Bonzanni, ENPICOM’s […]
The ENPICOM Platform seamlessly integrates AI, data management, and machine learning (ML) frameworks to foster collaboration among lab scientists, data scientists, and ML experts to drive innovation in biologics research.
ENPICOM secures additional funding to expand AI development and welcomes antibody discovery expert Dr. Colby Souders as a new investor.
ENPICOM partners with Erasmus Medical Center to develop nanobodies against cancer using their immune repertoire data analysis solutions.
Carterra and ENPICOM collaborate to streamline the analysis of sequencing and antibody screening data, focusing on identifying improved clinical-grade antibody candidates.
ENPICOM has secured additional funding to fuel international partnerships, enhance IGX Platform functionality, and introduce new generative AI solutions.
The Inno4Vac project aims to further develop vaccine technology on all fronts: from improving production facilities, to new in vivo and in vitro models for vaccine testing, to prediction of good vaccine candidates.
Being ISO 27001:2013 certified means that ENPICOM has a world-class security system in place. We are committed to pursuing excellence in our business operations, technology, and customer experience.
Genovac, a leading CRO/CMO that discovers, develops, and manufactures antibodies for therapeutic, diagnostic, and research market segments, will utilize ENPICOM’s IGX Platform for antibody discovery workflows.
ENPICOM has secured funding from BOP Capital to support the growth of their unique SaaS platform for therapeutic antibody discovery.
ENPICOM